25 U.S. 'Highest Conviction' Stocks – UBS

Seeking Alpha48minutes ago

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts

BenzingaDec 19 08:01 ET

Express News | HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

BenzingaDec 19 07:19 ET

Express News | Sarepta Therapeutics Inc - Anticipates Filing for Accelerated Approval of Srp-9003 in 2025

ReutersDec 18 08:30 ET

Express News | Sarepta Therapeutics Completes Enrollment in Emergene, a Phase 3 Clinical Study of Srp-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

ReutersDec 18 08:30 ET

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Sarepta TherapeuticsDec 18 00:00 ET